Stifel Nicolaus Reaffirms Buy Rating for BTG plc (BTG)
Stifel Nicolaus restated their buy rating on shares of BTG plc (LON:BTG) in a research report report published on Wednesday. Stifel Nicolaus currently has a GBX 800 ($10.35) price target on the stock.
Other equities research analysts have also issued reports about the stock. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 900 ($11.64) price target on shares of BTG plc in a report on Thursday, June 29th. Panmure Gordon lowered their price target on shares of BTG plc from GBX 809 ($10.46) to GBX 793 ($10.26) and set a buy rating on the stock in a report on Monday, May 22nd. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 775 ($10.02) price target on shares of BTG plc in a report on Thursday, May 18th. Jefferies Group LLC reaffirmed a buy rating and issued a GBX 775 ($10.02) price target on shares of BTG plc in a report on Tuesday, May 16th. Finally, Peel Hunt reaffirmed a hold rating and issued a GBX 630 ($8.15) price target on shares of BTG plc in a report on Tuesday, May 16th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of GBX 774.78 ($10.02).
BTG plc (LON BTG) opened at 693.50 on Wednesday. The company has a 50-day moving average price of GBX 665.12 and a 200-day moving average price of GBX 643.77. BTG plc has a one year low of GBX 528.36 and a one year high of GBX 738.50. The company’s market capitalization is GBX 2.67 billion.
In other BTG plc news, insider Rolf Soderstrom sold 22,624 shares of the company’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of GBX 649 ($8.39), for a total value of £146,829.76 ($189,898.81).
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.